Troriluzole
Modify Date: 2024-01-01 17:19:54
Troriluzole structure
|
Common Name | Troriluzole | ||
|---|---|---|---|---|
| CAS Number | 1926203-09-9 | Molecular Weight | 419.379 | |
| Density | 1.5±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C15H16F3N5O4S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of TroriluzoleTrigriluzole (BHV-4157) is a novel glutamate modulator for the treatment of mild-to-moderate Alzheimer’s disease (AD); Trigriluzole is a third-generation prodrug and new chemical entity that modulates glutamate, the most abundant excitatory neurotransmitter in the human body. Trigriluzole has a wide range of pharmacological actions, including interactions with several types of ion channels, cellular signaling mechanisms and facilitation of glutamate reuptake. Some potential targets related to trigriluzole’s mechanism of action include (1) reducing presynaptic glutamate release through actions at the voltage-gated ion channels, (2) facilitating glutamate uptake via EAATs located on glial cells, (3) enhancing transmission through synaptic AMPA receptors, (4) altering GABAergic neurotransmission, and (5) effecting neurotrophic agents such as BDNF. Anxiety Phase 3 Clinical |
| Name | BHV-4157 |
|---|---|
| Synonym | More Synonyms |
| Description | Trigriluzole (BHV-4157) is a novel glutamate modulator for the treatment of mild-to-moderate Alzheimer’s disease (AD); Trigriluzole is a third-generation prodrug and new chemical entity that modulates glutamate, the most abundant excitatory neurotransmitter in the human body. Trigriluzole has a wide range of pharmacological actions, including interactions with several types of ion channels, cellular signaling mechanisms and facilitation of glutamate reuptake. Some potential targets related to trigriluzole’s mechanism of action include (1) reducing presynaptic glutamate release through actions at the voltage-gated ion channels, (2) facilitating glutamate uptake via EAATs located on glial cells, (3) enhancing transmission through synaptic AMPA receptors, (4) altering GABAergic neurotransmission, and (5) effecting neurotrophic agents such as BDNF. Anxiety Phase 3 Clinical |
|---|---|
| Related Catalog | |
| Target |
glutamate[1] |
| In Vitro | Troriluzole is absorbed systemically and cleaves into riluzole by aminopeptidases[1]. |
| References |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Molecular Formula | C15H16F3N5O4S |
| Molecular Weight | 419.379 |
| Exact Mass | 419.087494 |
| LogP | 1.10 |
| Index of Refraction | 1.612 |
| Storage condition | 2-8°C |
| Glycinamide, glycylglycyl-N2-methyl-N-[6-(trifluoromethoxy)-2-benzothiazolyl]- |
| Glycylglycyl-N2-methyl-N-[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]glycinamide |
| S7H48S6K7H |
| BHV-4157 |
- Shanghai Nianxing Industrial Co., Ltd
- China
- Product Name: Troriluzole
- Price: Negotiable
- Purity: 99.0%
- Delivery: 10 Day
- Contact: Huang
- Email: sales@echemcloud.com
- DC Chemicals Limited
- China
- Product Name: Trigriluzole
- Price: $Inquiry/100mg $Inquiry/250mg $Inquiry/1g
- Purity: 98.0%
- Delivery: 3 Day
- Contact: Tony Cao
- Email: sales@dcchemicals.com
- ShangHai DC Chemicals Co.,Ltd
- China
- Product Name: Trigriluzole
- Price: ￥Inquiry/1g
- Purity: 98.9%
- Delivery: 1 Day
- Contact: Tony Lai
- Email: order@dcchemicals.com
Get all suppliers and price by the below link: